Volta Medical, GE Healthcare partner on AI-powered AFib treatments

Volta Medical, a French healthcare company focused on improving care for atrial fibrillation (AFib) patients, has agreed to integrate its artificial intelligence (AI) technologies into multiple GE Healthcare offerings.

As a result of this new collaboration, GE Healthcare’s Prucka 3 platform and CardioLab EP Recording System will both include Volta Medical’s new Volta AF-Xplorer, a digital AI companion that provides cardiologists with real-time assistance during complex procedures.

According to the two companies, working together made sense because the Volta AF-Xplorer technology compliments GE Healthcare’s CardioLab system. Both offerings were designed to help physicians manage patients with AFib and other heart rhythm issues.

GE Healthcare Prucka 3 platform

Image courtesy of GE Healthcare.

“Access to vast amounts of data empowers clinicians in their decision-making, but effectively using this data at the point of care can be challenging,” Devon Bream, GE Healthcare’s global general manager for invasive cardiology, said in a statement. “As GE HealthCare continues to advance our innovation to provide clinicians with precise signals in the electrophysiology lab, Volta Medical’s AI-driven solutions hold promise in consolidating and simplifying data, as well as assisting clinicians in making treatment decisions for their patients. I’m excited about our ongoing collaboration with Volta Medical as we work to innovate and transform electrophysiology labs to ensure patients receive the best possible care.”

“Our mission to combat complex heart rhythm diseases relies on optimizing interoperability,” added Théophile Mohr-Durdez, CEO and co-founder of Volta Medical. “Through this collaboration with GE HealthCare, we are advancing the frontier of current clinical applications in the field of electrophysiology.”

Volta Medical recently shared initial results from the TAILORED-AF clinical trial, which compared data from cardiac ablation procedures guided by the company’s AI algorithms to more conventional techniques. Overall, the AI method was associated with superior outcomes 12 months after treatment.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.